Skip to main content
SpringerLink
Log in

Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of CD19-specific CAR T-cells via TGF-β signaling

  • Research Article
  • Published:
Frontiers of Medicine Aims and scope Submit manuscript

Abstract

Tumor-derived exosomes (TEXs) enriched in immune suppressive molecules predominantly drive T-cell dysfunction and impair antitumor immunity. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment for refractory and relapsed hematological malignancies, but whether lymphoma TEXs have the same impact on CAR T-cell remains unclear. Here, we demonstrated that B-cell lymphoma-derived exosomes induce the initial activation of CD19-CAR T-cells upon stimulation with exosomal CD19. However, lymphoma TEXs might subsequently induce CAR T-cell apoptosis and impair the tumor cytotoxicity of the cells because of the upregulated expression of the inhibitory receptors PD-1, TIM3, and LAG3 upon prolonged exposure. Similar results were observed in the CAR T-cells exposed to plasma exosomes from patients with lymphoma. More importantly, single-cell RNA sequencing revealed that CAR T-cells typically showed differentiated phenotypes and regulatory T-cell (Treg) phenotype conversion. By blocking transforming growth factor β (TGF-β)-Smad3 signaling with TGF-β inhibitor LY2109761, the negative effects of TEXs on Treg conversion, terminal differentiation, and immune checkpoint expression were rescued. Collectively, although TEXs lead to the initial activation of CAR T-cells, the effect of TEXs suppressed CAR T-cells, which can be rescued by LY2109761. A treatment regimen combining CAR T-cell therapy and TGF-β inhibitors might be a novel therapeutic strategy for refractory and relapsed B-cell lymphoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Chong EA, Ruella M, Schuster SJ; Lymphoma Program Investigators at the University of Pennsylvania. Five-year outcomes for refractory b-cell lymphomas with car t-cell therapy. N Engl J Med 2021; 384(7): 673–674

    Article  PubMed  Google Scholar 

  2. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang ML, Chen CC, Kranick SM, Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015; 33(6): 540–549

    Article  CAS  PubMed  Google Scholar 

  3. Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, Levine JE, Qayed M, Grupp SA, Boyer M, De Moerloose B, Nemecek ER, Bittencourt H, Hiramatsu H, Buechner J, Davies SM, Verneris MR, Nguyen K, Brogdon JL, Bitter H, Morrissey M, Pierog P, Pantano S, Engelman JA, Winckler W. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med 2018; 24(10): 1504–1506

    Article  CAS  PubMed  Google Scholar 

  4. Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, Martinez NM, Harrington CT, Chung EY, Perazzelli J, Hofmann TJ, Maude SL, Raman P, Barrera A, Gill S, Lacey SF, Melenhorst JJ, Allman D, Jacoby E, Fry T, Mackall C, Barash Y, Lynch KW, Maris JM, Grupp SA, Thomas-Tikhonenko A. Convergence of acquired mutations and alternative splicing of cd19 enables resistance to cart-19 immunotherapy. Cancer Discov 2015; 5(12): 1282–1295

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Tong C, Zhang Y, Liu Y, Ji X, Zhang W, Guo Y, Han X, Ti D, Dai H, Wang C, Yang Q, Liu W, Wang Y, Wu Z, Han W. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. Blood 2020; 136(14): 1632–1644

    PubMed  PubMed Central  Google Scholar 

  6. Deng W, Chen P, Lei W, Xu Y, Xu N, Pu JJ, Liang A, Qian W. CD70-targeting CAR-T cells have potential activity against CD19-negative B-cell Lymphoma. Cancer Commun (Lond) 2021; 41(9): 925–929

    Article  PubMed  Google Scholar 

  7. Spiegel JY, Patel S, Muffly L, Hossain NM, Oak J, Baird JH, Frank MJ, Shiraz P, Sahaf B, Craig J, Iglesias M, Younes S, Natkunam Y, Ozawa MG, Yang E, Tamaresis J, Chinnasamy H, Ehlinger Z, Reynolds W, Lynn R, Rotiroti MC, Gkitsas N, Arai S, Johnston L, Lowsky R, Majzner RG, Meyer E, Negrin RS, Rezvani AR, Sidana S, Shizuru J, Weng WK, Mullins C, Jacob A, Kirsch I, Bazzano M, Zhou J, Mackay S, Bornheimer SJ, Schultz L, Ramakrishna S, Davis KL, Kong KA, Shah NN, Qin H, Fry T, Feldman S, Mackall CL, Miklos DB. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med 2021; 27(8): 1419–1431

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Cordoba S, Onuoha S, Thomas S, Pignataro DS, Hough R, Ghorashian S, Vora A, Bonney D, Veys P, Rao K, Lucchini G, Chiesa R, Chu J, Clark L, Fung MM, Smith K, Peticone C, Al-Hajj M, Baldan V, Ferrari M, Srivastava S, Jha R, Arce Vargas F, Duffy K, Day W, Virgo P, Wheeler L, Hancock J, Farzaneh F, Domning S, Zhang Y, Khokhar NZ, Peddareddigari VGR, Wynn R, Pule M, Amrolia PJ. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. Nat Med 2021; 27(10): 1797–1805

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Liu H, Lei W, Zhang C, Yang C, Wei J, Guo Q, Guo X, Chen Z, Lu Y, Young KH, Lu Z, Qian W. CD19-specific CAR T cells that express a PD-1/CD28 chimeric switch-receptor are effective in patients with PD-L1-positive B-cell lymphoma. Clin Cancer Res 2021; 27(2): 473–484

    Article  PubMed  Google Scholar 

  10. Yan X, Chen D, Wang Y, Guo Y, Tong C, Wei J, Zhang Y, Wu Z, Han W. Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies. Signal Transduct Target Ther 2022; 7(1): 98

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Milane L, Singh A, Mattheolabakis G, Suresh M, Amiji MM. Exosome mediated communication within the tumor microenvironment. J Control Release 2015; 219: 278–294

    Article  CAS  PubMed  Google Scholar 

  12. Mashouri L, Yousefi H, Aref AR, Ahadi AM, Molaei F, Alahari SK. Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. Mol Cancer 2019; 18(1): 75

    Article  PubMed  PubMed Central  Google Scholar 

  13. Whiteside TL. Tumor-derived exosomes and their role in cancer progression. Adv Clin Chem 2016; 74: 103–141

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Yang E, Wang X, Gong Z, Yu M, Wu H, Zhang D. Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression. Signal Transduct Target Ther 2020; 5(1): 242

    Article  PubMed  PubMed Central  Google Scholar 

  15. Ghosh AK, Secreto CR, Knox TR, Ding W, Mukhopadhyay D, Kay NE. Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood 2010; 115(9): 1755–1764

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Ma F, Vayalil J, Lee G, Wang Y, Peng G. Emerging role of tumorderived extracellular vesicles in T cell suppression and dysfunction in the tumor microenvironment. J Immunother Cancer 2021; 9(10): e003217

    Article  PubMed  PubMed Central  Google Scholar 

  17. Szczepanski MJ, Szajnik M, Welsh A, Whiteside TL, Boyiadzis M. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. Haematologica 2011; 96(9): 1302–1309

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Wieckowski EU, Visus C, Szajnik M, Szczepanski MJ, Storkus WJ, Whiteside TL. Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol 2009; 183(6): 3720–3730

    Article  CAS  PubMed  Google Scholar 

  19. Hao Q, Wu Y, Wu Y, Wang P, Vadgama JV. Tumor-derived exosomes in tumor-induced immune suppression. Int J Mol Sci 2022; 23(3): 1461

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Chen Z, You L, Wang L, Huang X, Liu H, Wei JY, Zhu L, Qian W. Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo. J Exp Clin Cancer Res 2018; 37(1): 190

    Article  PubMed  PubMed Central  Google Scholar 

  21. Hao Y, Chen P, Zhang X, Shao Y, Xu Y, Qian W. The effects of tumor-derived exosomes on T-cell function and efficacy of cancer immunotherapy. ImmunoMedicine 2021; 1(2): e1029

    Article  Google Scholar 

  22. Poggio M, Hu T, Pai CC, Chu B, Belair CD, Chang A, Montabana E, Lang UE, Fu Q, Fong L, Blelloch R. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell 2019; 177(2): 414–427.e13

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Stüber T, Monjezi R, Wallstabe L, Kühnemundt J, Nietzer SL, Dandekar G, Wöckel A, Einsele H, Wischhusen J, Hudecek M. Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer. J Immunother Cancer 2020; 8(1): e000676

    Article  PubMed  PubMed Central  Google Scholar 

  24. Aung T, Chapuy B, Vogel D, Wenzel D, Oppermann M, Lahmann M, Weinhage T, Menck K, Hupfeld T, Koch R, Trümper L, Wulf GG. Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proc Natl Acad Sci USA 2011; 108(37): 15336–15341

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Aitamer M, Akil H, Vignoles C, Branchaud M, Abraham J, Gachard N, Feuillard J, Jauberteau MO, Shirvani H, Troutaud D, Bentayeb H. CD20 expression, TrkB activation and functional activity of diffuse large B cell lymphoma-derived small extracellular vesicles. Br J Cancer 2021; 125(12): 1687–1698

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Cox MJ, Lucien F, Sakemura R, Boysen JC, Kim Y, Horvei P, Manriquez Roman C, Hansen MJ, Tapper EE, Siegler EL, Forsman C, Crotts SB, Schick KJ, Hefazi M, Ruff MW, Can I, Adada M, Bezerra E, Kankeu Fonkoua LA, Nevala WK, Braggio E, Ding W, Parikh SA, Kay NE, Kenderian SS. Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia. Mol Ther 2021; 29(4): 1529–1540

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Xhangolli I, Dura B, Lee G, Kim D, Xiao Y, Fan R. Single-cell analysis of CAR-T cell activation reveals a mixed TH1/TH2 response independent of differentiation. Genom Proteom Bioinf 2019; 17(2): 129–139

    Article  CAS  Google Scholar 

  28. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4+CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001; 194(5): 629–644

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Huber S, Schramm C, Lehr HA, Mann A, Schmitt S, Becker C, Protschka M, Galle PR, Neurath MF, Blessing M. TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J Immunol 2004; 173(11): 6526–6531

    Article  CAS  PubMed  Google Scholar 

  30. Tang N, Cheng C, Zhang X, Qiao M, Li N, Mu W, Wei XF, Han W, Wang H. TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight 2020; 5(4): e133977

    Article  PubMed  PubMed Central  Google Scholar 

  31. Chen W, Konkel JE. TGF-beta and ‘adaptive’ Foxp3+ regulatory T cells. J Mol Cell Biol 2010; 2(1): 30–36

    Article  CAS  PubMed  Google Scholar 

  32. Tone Y, Furuuchi K, Kojima Y, Tykocinski ML, Greene MI, Tone M. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol 2008; 9(2): 194–202

    Article  CAS  PubMed  Google Scholar 

  33. Park BV, Freeman ZT, Ghasemzadeh A, Chattergoon MA, Rutebemberwa A, Steigner J, Winter ME, Huynh TV, Sebald SM, Lee SJ, Pan F, Pardoll DM, Cox AL. TGFβ1-mediated smad3 enhances pd-1 expression on antigen-specific t cells in cancer. Cancer Discov 2016; 6(12): 1366–1381

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Oksvold MP, Kullmann A, Forfang L, Kierulf B, Li M, Brech A, Vlassov AV, Smeland EB, Neurauter A, Pedersen KW. Expression of B-cell surface antigens in subpopulations of exosomes released from B-cell lymphoma cells. Clin Ther 2014; 36(6): 847–862.e1

    Article  CAS  PubMed  Google Scholar 

  35. Ali S, Toews K, Schwiebert S, Klaus A, Winkler A, Grunewald L, Oevermann L, Deubzer HE, Tuns A, Jensen MC, Henssen AG, Eggert A, Schulte JH, Schwich E, Rebmann V, Schramm A, Kunkele A. Tumor-derived extracellular vesicles impair cd171-specific cd4+ car t cell efficacy. Front Immunol 2020; 11: 531

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Lin SC, Haga K, Zeng XL, Estes MK. Generation of CRISPR-Cas9-mediated genetic knockout human intestinal tissue-derived enteroid lines by lentivirus transduction and single-cell cloning. Nat Protoc 2022; 17(4): 1004–1027

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Tantalo DG, Oliver AJ, von Scheidt B, Harrison AJ, Mueller SN, Kershaw MH, Slaney CY. Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies. J Immunother Cancer 2021; 9(5): e002555

    Article  PubMed  PubMed Central  Google Scholar 

  38. Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O’Connor RS, Hwang WT, Pequignot E, Ambrose DE, Zhang C, Wilcox N, Bedoya F, Dorfmeier C, Chen F, Tian L, Parakandi H, Gupta M, Young RM, Johnson FB, Kulikovskaya I, Liu L, Xu J, Kassim SH, Davis MM, Levine BL, Frey NV, Siegel DL, Huang AC, Wherry EJ, Bitter H, Brogdon JL, Porter DL, June CH, Melenhorst JJ. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 2018; 24(5): 563–571

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Chen GM, Chen C, Das RK, Gao P, Chen CH, Bandyopadhyay S, Ding YY, Uzun Y, Yu W, Zhu Q, Myers RM, Grupp SA, Barrett DM, Tan K. Integrative bulk and single-cell profiling of premanufacture t-cell populations reveals factors mediating longterm persistence of CAR T-cell therapy. Cancer Discov 2021; 11(9): 2186–2199

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Yang C, Kim SH, Bianco NR, Robbins PD. Tumor-derived exosomes confer antigen-specific immunosuppression in a murine delayed-type hypersensitivity model. PLoS One 2011; 6(8): e22517

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, Maus MV, Fraietta JA, Zhao Y, June CH. Dominant-negative tgf-β receptor enhances psma-targeted human car t cell proliferation and augments prostate cancer eradication. Mol Ther 2018; 26(7): 1855–1866

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Chen X, Yang S, Li S, Qu Y, Wang HY, Liu J, Dunn ZS, Cinay GE, MacMullan MA, Hu F, Zhang X, Wang P. Secretion of bispecific protein of anti-PD-1 fused with TGF-β trap enhances antitumor efficacy of CAR-T cell therapy. Mol Ther Oncolytics 2021; 21: 144–157

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Proff J, Brey CU, Ensser A, Holter W, Lehner M. Turning the tables on cytomegalovirus: targeting viral Fc receptors by CARs containing mutated CH2-CH3 IgG spacer domains. J Transl Med 2018; 16(1): 26

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Boyiadzis M, Whiteside TL. Plasma-derived exosomes in acute myeloid leukemia for detection of minimal residual disease: are we ready? Expert Rev Mol Diagn 2016; 16(6): 623–629

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by the funds from the National Natural Science Foundation of China (Nos. 81830006, 82170219, and 81830004), and the Science Technology Department of Zhejiang Province (No. 2021C03117).

Author information

Author notes

  1. Yuanyuan Hao, Panpan Chen, and Shanshan Guo contributed equally to this study.

Authors and Affiliations

  1. Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310009, China

    Yuanyuan Hao, Panpan Chen, Shanshan Guo, Mengyuan Li, Xueli Jin, Minghuan Zhang, Wen Lei & Wenbin Qian

  2. Department of Hematology, Henan Provincial People’s Hospital, Zhengzhou University People’s Hospital, Zhengzhou, 450003, China

    Yuanyuan Hao

  3. Key Laboratory of Laboratory Medicine, Ministry of Education, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, 325000, China

    Wenhai Deng

  4. Department of Hematology, Tongji Hospital of Tongji University, Shanghai, 200065, China

    Ping Li & Aibin Liang

Authors
  1. Yuanyuan Hao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Panpan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shanshan Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mengyuan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xueli Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Minghuan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wenhai Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ping Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Wen Lei
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Aibin Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Wenbin Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Wen Lei, Aibin Liang or Wenbin Qian.

Ethics declarations

Conflicts of interests Yuanyuan Hao, Panpan Chen, Shanshan Guo, Mengyuan Li, Xueli Jin, Minghuan Zhang, Wenhai Deng, Ping Li, Wen Lei, Aibin Liang, and Wenbin Qian declare that they have no competing interests.

The study was approved by the responsible committee on human experimentation (institutional and national) and the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained from all patients for being included in the study. All institutional and national guidelines for the care and use of laboratory animals were followed.

Electronic supplementary materials

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hao, Y., Chen, P., Guo, S. et al. Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of CD19-specific CAR T-cells via TGF-β signaling. Front. Med. 18, 128–146 (2024). https://doi.org/10.1007/s11684-023-1010-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11684-023-1010-1

Keywords

Search

Navigation